UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date of Report: June 12, 2014
(Date of earliest event reported)
SciClone Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-19825 | 94-3116852 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) | ||
| 950 Tower Lane, Suite 900, Foster City, CA |
94404 | |||
| (Address of principal executive offices) | (Zip Code) | |||
(650) 358-3456
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07 | Submission of Matters to a vote of Security Holders. |
At the 2014 Annual Meeting of Stockholders of the Company held on June 12, 2014 (the “Annual Meeting”), the matters on which the stockholders voted, in person or by proxy were:
| (i) | To elect six nominees as directors to serve until the next Annual Meeting and until their successors have been elected and qualified; |
| (ii) | To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement; |
| (iii) | To ratify the selection of PricewaterhouseCoopers Zhong Tian LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014. |
The six nominees were elected, the compensation of named executive officers was approved and the appointment of the independent registered public accounting firm was ratified. The results of the voting were as follows:
| Election of Directors |
Votes For |
Votes Withheld |
Broker Non-votes |
|||||||||
| Jon S. Saxe |
25,185,622 | 9,846,407 | 7,484,538 | |||||||||
| Friedhelm Blobel, Ph.D. |
34,015,695 | 1,016,334 | 7,484,538 | |||||||||
| Nancy T. Chang, Ph.D. |
34,593,591 | 438,438 | 7,484,538 | |||||||||
| Richard J. Hawkins |
25,143,410 | 9,888,619 | 7,484,538 | |||||||||
| Gregg A. Lapointe |
26,981,526 | 8,050,503 | 7,484,538 | |||||||||
| Simon Li |
27,587,159 | 7,444,870 | 7,484,538 | |||||||||
| Votes For |
Votes Against |
Abstentions | Broker Non-votes |
|||||||||||||
| Approval of the Executive Compensation |
30,773,213 | 2,271,840 | 1,986,976 | 7,484,538 | ||||||||||||
| Votes For |
Votes Against |
Abstentions | ||||||||||
| Ratification of Appointment of Independent Registered Public Accounting Firm |
42,174,606 | 286,026 | 55,935 | |||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 12, 2014 | SCICLONE PHARMACEUTICALS, INC. | |||||
| By: | /s/ Wilson W. Cheung | |||||
| Wilson W. Cheung | ||||||
| Chief Financial Officer and Senior Vice President, Finance | ||||||